AHU-377 is a prodrug that is metabolized to the active form, LBQ657; this compound inhibits neprilysin, preventing degradation of atrial natriuretic peptide (ANP) and brain-derived natriuretic peptide (BNP). AHU-377 displays vasodilatory and antihypertensive properties. AHU-377 is currently in clinical trials as a potential treatment for several cardiovascular indications such as congestive heart failure (CHF) and hypertension.
| Cas No. | 149709-62-6 |
|---|---|
| Purity | ≥99% |
| Formula | C24H29NO5 • C4H11NO3 |
| Formula Wt. | 532.63 |
| Synonym | AHU377, Sacubitril |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A3080 Info Sheet PDF |
|---|
Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014 Dec;2(6):663-70. PMID: 25306450.
Monge M, Lorthioir A, Bobrie G, et al. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013 Dec;14(4):285-9. PMID: 24222656.
Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010 Apr 10;375(9722):1255-66. PMID: 20236700.
